J Am Board Fam Med. 2026 Aug;39(1):165782. doi: 10.3122/jabfm.2025.250473R1.
ABSTRACT
A commonly used GLP-1 agonist, semaglutide, reduces the risk of adverse cardiovascular outcomes in non-diabetic individuals with obesity and pre-existing cardiovascular disease.
PMID:42624784 | DOI:10.3122/jabfm.2025.250473R1